Resolute Capital Asset Partners LLC Replimune Group, Inc. Transaction History

Resolute Capital Asset Partners LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$15.65 - $24.1 $602,884 - $928,404	-38,523 Reduced 46.69%	43,977 $1.02 Million
Q1 2023 May 15, 2023	SELL	$17.48 - $29.09 $2.23 Million - $3.71 Million	-127,500 Reduced 60.71%	82,500 $1.46 Million
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $3.59 Million - $5.86 Million	210,000 New	210,000 $5.71 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Resolute Capital Asset Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Resolute Capital Asset Partners LLC with notifications on news.